Raymond James analyst Jayson Bedford maintained a Buy rating on Tandem Diabetes Care (TNDM) today and set a price target of $124.00. The company’s shares closed last Thursday at $119.64, close to its 52-week high of $123.74.
According to TipRanks.com, Bedford is a 5-star analyst with an average return of 15.6% and a 68.8% success rate. Bedford covers the Healthcare sector, focusing on stocks such as Cardiovascular Systems, Merit Medical Systems, and Integra Lifesciences.
Currently, the analyst consensus on Tandem Diabetes Care is a Strong Buy with an average price target of $125.20, a 6.7% upside from current levels. In a report released yesterday, Oppenheimer also maintained a Buy rating on the stock with a $130.00 price target.
See today’s analyst top recommended stocks >>
Based on Tandem Diabetes Care’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $109 million and GAAP net loss of $27.11 million. In comparison, last year the company earned revenue of $93.26 million and had a GAAP net loss of $1.51 million.
Based on the recent corporate insider activity of 72 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its flagship product, t:slim X2 Insulin Delivery System, operates as a small insulin pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.